INDV
Indivior Pharmaceuticals Inc
Drug Manufacturers - Specialty & Generic
Market Cap$4.94B
5Y Perf.+890.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
INDV vs BHC
Revenue, margins, valuation, and 5-year total return — side by side.
BHC
Bausch Health Companies Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$2.14B
5Y Perf.-69.0%
INDV vs BHC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | INDV | BHC |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.94B | $2.14B |
| Revenue (TTM) | $1.29B | $10.55B |
| Net Income (TTM) | $251M | $-1.19B |
| Gross Margin | 83.1% | 61.7% |
| Operating Margin | 33.3% | 22.9% |
| Forward P/E | 12.7x | 1.3x |
| Total Debt | $351M | $21.21B |
| Cash & Equiv. | $195M | $1.32B |
INDV vs BHC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
INDV
BHC
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Indivior Pharmaceut… (INDV) | 100 | 990.0 | +890.0% |
| Bausch Health Compa… (BHC) | 100 | 31.0 | -69.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INDV vs BHC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: INDV leads in 4 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Bausch Health Companies Inc. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
INDV
Indivior Pharmaceuticals Inc
The Income Pick
INDV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.68
- Rev growth 4.3%, EPS growth 108.3%, 3Y rev CAGR 11.2%
- 281.7% 10Y total return vs BHC's -79.6%
Best for: income & stability and growth exposure
BHC
Bausch Health Companies Inc.
The Growth Leader
BHC is the clearest fit if your priority is growth and value.
- 8.5% revenue growth vs INDV's 4.3%
- Lower P/E (1.3x vs 12.7x)
Best for: growth and value
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BHC | 8.5% revenue growth vs INDV's 4.3% |
| Value | BHC | Lower P/E (1.3x vs 12.7x) |
| Quality / Margins | INDV | 19.4% margin vs BHC's -11.3% |
| Stability / Safety | INDV | Beta 0.68 vs BHC's 1.02 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | INDV | +244.9% vs BHC's +21.8% |
| Efficiency (ROA) | INDV | 19.1% ROA vs BHC's -4.5%, ROIC 342.7% vs 8.2% |
INDV vs BHC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
INDV vs BHC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLINDVLAGGINGBHC
BHCBausch Health Compani…
2leads
INDVIndivior Pharmaceutic…
4leads
6 Total Categories
CATEGORYLEADERvs BHCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
INDV5/6
Valuation MetricsMultiples, price ratios, and targets
BHC4/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
INDV6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
INDV6/6
Risk & VolatilityBeta, volatility, and downside exposure
INDV2/2
Analyst OutlookRatings, price targets, and dividends
BHC1/1
Income & Cash Flow (Last 12 Months)
INDV leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BHC is the larger business by revenue, generating $10.6B annually — 8.2x INDV's $1.3B. INDV is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to BHC's -11.3%. On growth, INDV holds the edge at +19.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | INDVIndivior Pharmace… | BHCBausch Health Com… |
|---|---|---|
| RevenueTrailing 12 months | $1.3B | $10.6B |
| EBITDAEarnings before interest/tax | $447M | $3.6B |
| Net IncomeAfter-tax profit | $251M | -$1.2B |
| Free Cash FlowCash after capex | -$185M | $990M |
| Gross MarginGross profit ÷ Revenue | +83.1% | +61.7% |
| Operating MarginEBIT ÷ Revenue | +33.3% | +22.9% |
| Net MarginNet income ÷ Revenue | +19.4% | -11.3% |
| FCF MarginFCF ÷ Revenue | -14.3% | +9.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.2% | +10.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +81.6% | -22.7% |
INDV leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
BHC leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
At 13.3x trailing earnings, BHC trades at a 45% valuation discount to INDV's 24.1x P/E. On an enterprise value basis, BHC's 6.4x EV/EBITDA is more attractive than INDV's 17.9x.
| Metric | INDVIndivior Pharmace… | BHCBausch Health Com… |
|---|---|---|
| Market CapShares × price | $4.9B | $2.1B |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $22.0B |
| Trailing P/EPrice ÷ TTM EPS | 24.15x | 13.31x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.65x | 1.32x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 17.88x | 6.38x |
| Price / SalesMarket cap ÷ Revenue | 3.99x | 0.20x |
| Price / BookPrice ÷ Book value/share | — | 5.71x |
| Price / FCFMarket cap ÷ FCF | — | 2.13x |
BHC leads this category, winning 4 of 4 comparable metrics.
Profitability & Efficiency
INDV leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), BHC scores 7/9 vs INDV's 4/9, reflecting strong financial health.
| Metric | INDVIndivior Pharmace… | BHCBausch Health Com… |
|---|---|---|
| ROE (TTM)Return on equity | — | +5.9% |
| ROA (TTM)Return on assets | +19.1% | -4.5% |
| ROICReturn on invested capital | +3.4% | +8.2% |
| ROCEReturn on capital employed | +79.1% | +10.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | — | 56.36x |
| Net DebtTotal debt minus cash | $156M | $19.9B |
| Cash & Equiv.Liquid assets | $195M | $1.3B |
| Total DebtShort + long-term debt | $351M | $21.2B |
| Interest CoverageEBIT ÷ Interest expense | 10.88x | 1.43x |
INDV leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
INDV leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INDV five years ago would be worth $36,837 today (with dividends reinvested), compared to $2,039 for BHC. Over the past 12 months, INDV leads with a +244.9% total return vs BHC's +21.8%. The 3-year compound annual growth rate (CAGR) favors INDV at 25.4% vs BHC's -1.5% — a key indicator of consistent wealth creation.
| Metric | INDVIndivior Pharmace… | BHCBausch Health Com… |
|---|---|---|
| YTD ReturnYear-to-date | +10.8% | -20.6% |
| 1-Year ReturnPast 12 months | +244.9% | +21.8% |
| 3-Year ReturnCumulative with dividends | +97.0% | -4.4% |
| 5-Year ReturnCumulative with dividends | +268.4% | -79.6% |
| 10-Year ReturnCumulative with dividends | +281.7% | -79.6% |
| CAGR (3Y)Annualised 3-year return | +25.4% | -1.5% |
INDV leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
INDV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INDV is the less volatile stock with a 0.68 beta — it tends to amplify market swings less than BHC's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INDV currently trades 96.6% from its 52-week high vs BHC's 65.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INDVIndivior Pharmace… | BHCBausch Health Com… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 1.02x |
| 52-Week HighHighest price in past year | $41.00 | $8.69 |
| 52-Week LowLowest price in past year | $10.63 | $4.41 |
| % of 52W HighCurrent price vs 52-week peak | +96.6% | +65.9% |
| RSI (14)Momentum oscillator 0–100 | 79.6 | 52.3 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 1.8M |
INDV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
BHC leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates INDV as "Buy" and BHC as "Buy". Consensus price targets imply 39.7% upside for BHC (target: $8) vs 12.8% for INDV (target: $45).
| Metric | INDVIndivior Pharmace… | BHCBausch Health Com… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $44.67 | $8.00 |
| # AnalystsCovering analysts | 3 | 38 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
BHC leads this category, winning 1 of 1 comparable metric.
Key Takeaway
INDV leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BHC leads in 2 (Valuation Metrics, Analyst Outlook).
Best OverallIndivior Pharmaceuticals Inc (INDV)Leads 4 of 6 categories
Loading custom metrics...
INDV vs BHC: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is INDV or BHC a better buy right now?
For growth investors, Bausch Health Companies Inc.
(BHC) is the stronger pick with 8. 5% revenue growth year-over-year, versus 4. 3% for Indivior Pharmaceuticals Inc (INDV). Bausch Health Companies Inc. (BHC) offers the better valuation at 13. 3x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Indivior Pharmaceuticals Inc (INDV) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INDV or BHC?
On trailing P/E, Bausch Health Companies Inc.
(BHC) is the cheapest at 13. 3x versus Indivior Pharmaceuticals Inc at 24. 1x. On forward P/E, Bausch Health Companies Inc. is actually cheaper at 1. 3x.
03Which is the better long-term investment — INDV or BHC?
Over the past 5 years, Indivior Pharmaceuticals Inc (INDV) delivered a total return of +268.
4%, compared to -79. 6% for Bausch Health Companies Inc. (BHC). Over 10 years, the gap is even starker: INDV returned +281. 7% versus BHC's -79. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INDV or BHC?
By beta (market sensitivity over 5 years), Indivior Pharmaceuticals Inc (INDV) is the lower-risk stock at 0.
68β versus Bausch Health Companies Inc. 's 1. 02β — meaning BHC is approximately 50% more volatile than INDV relative to the S&P 500.
05Which is growing faster — INDV or BHC?
By revenue growth (latest reported year), Bausch Health Companies Inc.
(BHC) is pulling ahead at 8. 5% versus 4. 3% for Indivior Pharmaceuticals Inc (INDV). On earnings-per-share growth, the picture is similar: Indivior Pharmaceuticals Inc grew EPS 108. 3% year-over-year, compared to 430. 8% for Bausch Health Companies Inc.. Over a 3-year CAGR, INDV leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INDV or BHC?
Indivior Pharmaceuticals Inc (INDV) is the more profitable company, earning 16.
9% net margin versus 1. 5% for Bausch Health Companies Inc. — meaning it keeps 16. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INDV leads at 21. 4% versus 21. 3% for BHC. At the gross margin level — before operating expenses — INDV leads at 80. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INDV or BHC more undervalued right now?
On forward earnings alone, Bausch Health Companies Inc.
(BHC) trades at 1. 3x forward P/E versus 12. 7x for Indivior Pharmaceuticals Inc — 11. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BHC: 39. 7% to $8. 00.
08Which pays a better dividend — INDV or BHC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is INDV or BHC better for a retirement portfolio?
For long-horizon retirement investors, Indivior Pharmaceuticals Inc (INDV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
68), +281. 7% 10Y return). Both have compounded well over 10 years (INDV: +281. 7%, BHC: -79. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INDV and BHC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INDV is a small-cap quality compounder stock; BHC is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(INDV: 19.2% · BHC: 10.5%)P/E Ratio<
x
(INDV: 24.1x · BHC: 13.3x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.